The Repository@Hull is intended to be an Open Access showcase for the published research output of the university. Whenever possible, refereed documents accepted for publication, or finished artistic compositions presented in public, will be made available here in full digital format, and hyperlinks to standard published versions will be provided.
HDAC inhibitor confers radiosensitivity to prostate stem-like cells (2013)
Journal Article
Frame, F. M., Pellacani, D., Collins, A. T., Simms, M. S., Mann, V. M., Jones, G., …Maitland, N. J. (2013). HDAC inhibitor confers radiosensitivity to prostate stem-like cells. The British journal of cancer / Cancer Research Campaign, 109(12), 3023-3033. https://doi.org/10.1038/bjc.2013.691Background: Radiotherapy can be an effective treatment for prostate cancer, but radiorecurrent tumours do develop. Considering prostate cancer heterogeneity, we hypothesised that primitive stem-like cells may constitute the radiation-resistant fract... Read More
DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation (2014)
Journal Article
Pellacani, D., Kestoras, D., Droop, A. P., Frame, F. M., Berry, P. A., Lawrence, M. G., …Maitland, N. J. (2014). DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death and Differentiation, 21(5), 761-773. https://doi.org/10.1038/cdd.2013.202Prostate cancer (CaP) is mostly composed of luminal-like differentiated cells, but contains a small subpopulation of basal cells (including stem-like cells), which can proliferate and differentiate into luminal-like cells. In cancers, CpG island hype... Read More
Low temperature plasma: a novel focal therapy for localized prostate cancer? (2014)
Journal Article
Hirst, A. M., Frame, F. M., Maitland, N. J., & O’Connell, D. (2014). Low temperature plasma: a novel focal therapy for localized prostate cancer?. Biomed research international, 2014, https://doi.org/10.1155/2014/878319Despite considerable advances in recent years for the focal treatment of localized prostate cancer, high recurrence rates and detrimental side effects are still a cause for concern. In this review, we compare current focal therapies to a potentially... Read More
Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells (2015)
Journal Article
Hirst, A. M., Simms, M. S., Mann, V. M., Maitland, N. J., O'Connell, D., & Frame, F. M. (2015). Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells. The British journal of cancer / Cancer Research Campaign, 112(9), 1536-1545. https://doi.org/10.1038/bjc.2015.113Background: In recent years, the rapidly advancing field of low-temperature atmospheric pressure plasmas has shown considerable promise for future translational biomedical applications, including cancer therapy, through the generation of reactive ox... Read More
The Ethical Dimension in Political Market Orientation: A Framework for Evaluating the Impact of India's Look East Policy on Regional Income Convergence (2019)
Journal Article
Choudhury, H., Kopacsi, L., Saxena, G., & Mishra, N. (in press). The Ethical Dimension in Political Market Orientation: A Framework for Evaluating the Impact of India's Look East Policy on Regional Income Convergence. Journal of business ethics, -. https://doi.org/10.1007/s10551-019-04169-wIn this paper, we employ what we term as 'the ethical dimension in political market orientation (PMO)' framework to underline how an integration of information from relevant stakeholder groups can inform the formulation of market-oriented, yet ethica... Read More
About Hull Repository
© 2018 Worktribe
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)